RSS REGENXBIO, Nippon Shinyaku Join For Development, Commercialization Of RGX-121, And RGX-111

[Crax Bot]

REGENXBIO Inc. (RGNX) has entered into a strategic partnership with Nippon Shinyaku for the development and commercialization of two key therapies: RGX-121, targeting Mucopolysaccharidosis II (Hunter syndrome), and RGX-111, aimed at treating Mucopolysaccharidosis I. Under this agreement, Nippon Shinyaku will be responsible for the commercialization of these therapies within the specified Licensed Territory, while REGENXBIO will spearhead the future clinical development of both RGX-121 and RGX-111.

As part of the agreement's financial terms, REGENXBIO is set to receive an immediate payment of $110 million at the time of closing. Additionally, the company stands to earn up to a further $700 million upon achieving certain defined milestones. This total includes $40 million tied to potential development and regulatory milestones, along with $660 million linked to sales milestones. Furthermore, REGENXBIO will benefit from substantial double-digit royalties based on net sales generated in the U.S. and Asian markets.

The material has been provided by InstaForex Company - www.instaforex.com

Click to read more...